GIP
OPNT

Granite Investment Partners’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Granite Investment Partners’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-14,453
Closed -$191K – 375
2019
Q2 		$191K Sell
14,453
-12,690
-47% -$154K 0.01% 330
2019
Q1 		$356K Buy
+27,143
New +$396K 0.02% 319

Other funds holding OPNT

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Granite Investment Partners's OPNT Position: Q3 2019 in Review

Granite Investment Partners sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q3 2019, closing a stake of 14,453 shares — an estimated $191K sold.

Granite Investment Partners first reported a position in OPNT in Q1 2019 and held it in 2 quarters. The position peaked at $356K in Q1 2019. 25 funds tracked by Wall St. Rank hold OPNT as of Q3 2019.

  • Granite Investment Partners reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Granite Investment Partners sold 14,453 Opiant Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $191K.
  • Granite Investment Partners first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 2 quarters.
  • Granite Investment Partners's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $356K in Q1 2019.
  • 25 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Granite Investment Partners's 13F filing for Q3 2019, filed 12 Nov 2019.